Search results
Results from the WOW.Com Content Network
“The nation’s largest nursing home pharmacy, Omnicare Inc. of Covington, Kentucky, will pay $98 million,” Assistant Attorney General Tony West announced, to settle charges that it “solicited and received kickbacks from a pharmaceutical manufacturer, Johnson & Johnson (J&J), in exchange for agreeing to recommend that physicians prescribe Risperdal, a J&J antipsychotic drug, to nursing ...
Risperidone, sold under the brand name Risperdal among others, is an atypical antipsychotic [2] used to treat schizophrenia and bipolar disorder, [2] as well as aggressive and self-injurious behaviors associated with autism spectrum disorder. [9] It is taken either by mouth or by injection (i.e., subcutaneous or intramuscular). [2]
On December 19, 2003—10 days after a Janssen salesman, making his bi-weekly visits, had dropped off another 1,592 sample doses for Austin Pledger’s doctor to try out on new patients—Janssen’s regulatory team had gone back to the FDA, in yet another effort to get children legally on to the Risperdal label.
Risperdal, Invega, Nesiritide: False Claims Act, FDCA 2012 Abbott Laboratories [8] $1.5 billion Off-label promotion Depakote: False Claims Act, FDCA 2009 Eli Lilly [9] $1.4 billion Off-label promotion Zyprexa: False Claims Act, FDCA 2001 TAP Pharmaceutical Products [10] $875 million Medicare fraud, kickbacks Lupron
Another goal for the coming year was to “maximize and grow Risperdal’s market leadership in geriatrics and long term care.” Risperdal was already well ahead of Zyprexa in dementia market share, with 50 percent of the entire market. The goal was to boost that share still higher, to 57 percent, with sales of $302 million.
Risperdal/Invega/ Nesiritide: Johnson & Johnson [6] $2,200,000,000 $1.72 billion civil ($2.2 billion with criminal component) Off-label promotion/kickbacks: False Claims Act/FDCA 2009 2 3 Bextra/Geodon/ Zyvox/Lyrica: Pfizer [7] $2,300,000,000 $1 billion civil ($2.3 billion with criminal component) Off-label promotion/kickbacks: False Claims Act ...
Johnson & Johnson (NYS: JNJ) has come to terms with the Justice Department on one Risperdal marketing charge. It's a single misdemeanor, stemming from a long-running investigation of allegations ...
As with that first case brought in 2006 for the boy in New Jersey, Sheller’s injury claims were still mostly about diabetes. And they were looking increasingly unlikely to bring in big verdicts or settlements because of the difficulty of proving that while Risperdal caused weight gain—which the company had clearly warned about on its label ...